William Wallace: Why Most of the World isn’t Getting Enough Omega-3
William Wallace, Director of Product Development and Scientific Affairs at ProHealth Longevity, shared on LinkedIn:
“Most of the world isn’t getting enough omega-3, and the problem isn’t optimization. It’s the floor.

A global review of national and international nutrition guidelines shows that ~76% of people worldwide fail to meet the recommended intake of omega-3 fatty acids EPA and DHA. This gap isn’t subtle, it represents one of the most widespread nutrient shortfalls affecting otherwise healthy populations.
What’s often misunderstood is what the recommendation actually represents.
The most frequently cited target (~250 mg per day of combined EPA + DHA) is not a “maximum benefit” dose.
It is the minimum intake consistently associated with measurable health protection, particularly a reduced risk of fatal coronary heart disease and sudden cardiac death.
Large population datasets show that cardiovascular risk declines as EPA+DHA intake increases, but this decline plateaus around 250 mg/day. Below that level, risk rises. Above it, additional benefits may occur, but the core mortality signal is already established.
That is why organizations such as FAO/WHO, EFSA, and numerous national health authorities converge on this number.
In other words:
This guideline defines the bare minimum needed to experience benefit, not an optimal or therapeutic dose.
Yet most people aren’t even reaching that baseline.
Food-based strategies alone often fall short due to:
Low oily fish consumption
Cultural and geographic barriers
Sustainability concerns
Confusing and inconsistent guidelines between countries
As a result, the review highlights that supplementation or enriched foods are often required, particularly during pregnancy and in individuals with low fish intake.
Pregnancy recommendations build on the same baseline, typically advising 250 mg EPA+DHA plus an additional 100–200 mg DHA, reflecting increased biological demand, not a different philosophy.
Omega-3s support health across the entire life course, from fetal neurodevelopment and visual function to cardiovascular health, immune regulation, and healthy aging. But none of those benefits matter if people never reach the threshold where benefit begins.
This isn’t about doing everything possible.
It’s about doing enough to matter.”
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Jul 10, 2026, 15:34Joy Celebre: A New Opportunity in Hemostasis Leadership
-
Jul 10, 2026, 15:11Thirunavukkarasu Angappan: The Geopolitics of Plasma Supply and Self-Sufficiency
-
Jul 10, 2026, 14:51Danielle Boyle: Global Collaboration Takes Center Stage at ISTH 2026
-
Jul 10, 2026, 14:29Beril Awuor: The Functional Architecture of Blood and Its Physiological Significance
-
Jul 10, 2026, 14:15Arezoo Esteki: The Rising Role of Platelet-Rich Plasma in Precision Regenerative Care
-
Jul 10, 2026, 14:04Morgan Fogarty: A New Era of Continuous Bedside Brain Monitoring After Stroke
-
Jul 10, 2026, 13:50Nikki Veale: The Digital Stroke Recovery Programme in Cornwall Is Out Now
-
Jul 10, 2026, 13:43Fiona Bardon: Shaping Better Long-Term Stroke Care Through the CLASP Pathway
-
Jul 10, 2026, 13:22Rohan Arora: Can Artificial Intelligence Improve Informed Consent in Stroke Clinical Trials?